Teva
Teva collaborates on skin disease treatment, releases targets
Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a phase 1b trial for the treatment of vitiligo
Teva seeks startups to help solve global pharmaceutical challenges
Placing the focus on the therapist
Does a common heart attack pill help everyone? Studies disagree
Teva Naot launches store in Vancouver, Canada
In 2019, Teva Naot sold about 100,000 pairs of shoes in its stores and to retailers, and through the website in the Canadian market.
Teva’s proposed settlement could cost drugmaker pennies on the dollar
Israel-based Teva is looking to reach a nationwide settlement over its role in selling opioid painkillers, together with drugmaker Johnson & Johnson and the three largest U.S. drug distributors.
Teva shares surge amid hopes of $23 billion opioid claims settlement
Teva stocks also closed up 8.67% on the New York Stock Exchange on Monday amid growing optimism.
Opioid settlement talks fail with Teva, landmark trial expected Monday
After nearly 11 hours of negotiations, Pennsylvania Attorney General Josh Shapiro told reporters it was “profoundly disappointing” that local governments would not go along with a settlement.
Teva proposes $15 billion deal to settle opioid claims
The proposed settlement comes only days ahead of a landmark federal trial in Cleveland, Ohio, against the company and five drug distributors.
Teva joins medical cannabis market with Israel distribution deal
Under the agreement announced Friday, S.L.E. will distribute Canndoc's GMP-approved products to clients in Israel, including hospitals, health maintenance organizations (HMOs) and all pharmacies.
Teva launches generic version of EpiPen for young children
The drugmaker has been struggling with falling prices of generics and faces lawsuits that allege it helped fuel the U.S. opioid addiction epidemic.
Teva woes continue amid congressional probe, negative outlook
According to the May lawsuit filed by Connecticut Attorney-General William Tong, Teva significantly raised prices on approximately 112 different generic drugs between July 2013 and January 2015.
What’s ‘down’ with Teva?
Yet, as of late 2018, the company announced it would be laying off 1,700 of its Israel-based workers.
Oklahoma judge approves Teva's $85 million opioid settlement
The case is one of around 2,000 by state and local governments seeking to hold drugmakers responsible for an epidemic in the US.